RxDoctor Payments Data

Margaret Wierman, MD

Endocrinology, Diabetes & Metabolism · Aurora, CONPI 1639269319

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $30,578 of the $35,767 with a category attached, or 85.5%. Novo Nordisk accounts for 73.5% of it on its own, with 3 other manufacturers making up the rest.

$35,767in general payments, 2019–2025

Across 29 payments — averaging $1233.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$26K
  • Neurocrine Biosciences, Inc.$6K
  • HRA Pharma RARE Diseases$2K
  • Pfizer$1K
$30,887in research payments, 2019–2025

Across 10 payments — averaging $3088.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • OPKO Pharmaceuticals, LLC$16K
  • Corcept Therapeutics$14K

What the payments were for

  • Consulting fees$30,57885%
  • Speaking & faculty fees$1,2503%
  • Travel & lodging$3,0198%
  • Food & beverage$9213%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk15$26,274
Neurocrine Biosciences, Inc.12$6,243
HRA Pharma RARE Diseases1$2,000
Pfizer1$1,250

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,767 in reported general payments places this provider in the 85th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.

See all endocrinology, diabetes & metabolism providers in Colorado

Medicare billing

Part B allowed, 2024
$14,395
Medicare patients
72
Services billed
112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LysodrenMitotane64$164,793
OzempicSemaglutide17$18,365
Cabergoline37$6,005
Testosterone27$4,541
SynthroidLevothyroxine Sodium23$2,846
Prednisone84$1,122
Levothyroxine Sodium81$1,050
Fludrocortisone Acetate27$953
Omeprazole19$294
Atorvastatin Calcium19$284
Metformin Hcl21$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$26,274$18,36517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.

Other endocrinology, diabetes & metabolism in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →